Trials / NCT02338973
Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)
Terminated Phase 1 / Phase 2 Drug / neuroprotection
- Sponsor
- National Eye Institute (NEI)
- Treatment
- Interferon gamma-1b
- Gene
- NR2E3
- Conditions
- Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
- Ages
- 12 Years to no upper limit
- Enrollment
- 4 participants
- Started
- 2015-01-14
- Main results expected
- 2018-06-01
- Results posted
- Yes
- Record last updated
- 2019-08-13
What the study is testing
Background:
- People with rod-cone dystrophy (RCD) or enhanced S-cone syndrome (ESCS) have excess fluid under the retina of their eye. This can cause vision loss. The medicine interferon gamma-1b may help people with these diseases.
Objectives:
- To see if interferon gamma-1b eyedrops are safe for people with RCD or ESCS. To see if the medicine can decrease retina fluid and help prevent vision loss.
Eligibility:
- People at least 12 years old with RCD or ESCS. Those with ESCS must have two mutations in the NR2E3 gene.
Design:
- Participants will be screened with medical history, physical exam, eye exam, and blood tests.
- Participants will stay at NIH for 3 days and get the first eyedrops.
- Participants will give themselves 4 study eyedrops 4 times daily for 2 weeks and keep a diary.
- Participants will have 5 outpatient visits over 8 weeks, 2 of which are telephone assessments. They may have:
- Repeats of screening tests.
- Questionnaires.
- Small piece of skin removed.
- Eye exams, including eye dilation and tasks on computer screens.
- Fluorescein angiography. A dye injected into an arm vein will travel to the blood vessels in the eyes. A camera will take pictures.
- Electroretinography. Participants will sit in the dark wearing eyepatches. A small electrode will be taped to the forehead. After 30 minutes, researchers will remove the eyepatches and put in numbing eyedrops and contact lenses. Participants will watch flashing lights.
- Electrooculography. Electrodes will be attached outside of the eyes and eye function will be measured in the dark and the light.
- Participants will have a follow-up visit after 52 weeks.
Where it runs
United States (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland